Advertising

From Awareness to Advertising: Re-examining the GLP-1 drug boundaries (Part 1)

Summary: Part 1 of this Article examines the CDSCO’s March 2026 Advisory directed at manufacturers, importers and marketing authorisation holders of GLP-1 receptor agonists, reinforcing that regulatory scrutiny of prescription-only medicine promotion will focus on substance over form. It prohibits all advertising — whether direct, surrogate, or influencer-led — that create brand recall among public.

Continue Reading From Awareness to Advertising: Re-examining the GLP-1 drug boundaries (Part 1)

Background

The European Court of Justice (“CJEU”) in mid-2023 passed a landmark judgment in Meta Platforms Inc. v. Bundeskartellamt[1], by imposing strict restrictions on social media entities using personal data of consumer’s for targeting them with personalised advertisements through their platforms. This ruling struck at the core revenue model of many big technology organisations.   

Continue Reading The Great Reset: What Lies in Store for Targeted Advertising?